These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1482149)

  • 101. Penetration of ceftriaxone into human pleural fluid.
    Benoni G; Arosio E; Cuzzolin L; Vaona B; Raimondi MG; Lechi A
    Antimicrob Agents Chemother; 1986 May; 29(5):906-8. PubMed ID: 3729347
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Daily variations in ceftriaxone pharmacokinetics in rats.
    Rebuelto M; Ambros L; Rubio M
    Antimicrob Agents Chemother; 2003 Feb; 47(2):809-12. PubMed ID: 12543699
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients.
    Fauvelle F; Lortholary O; Tod M; Guillevin L; Louchahi M; Léon A; Petitjean O
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1519-22. PubMed ID: 7979282
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Effects of diclofenac on ceftriaxone pharmacokinetics in humans.
    Merle-Melet M; Bresler L; Lokiec F; Dopff C; Boissel P; Dureux JB
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2331-3. PubMed ID: 1444314
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients.
    Deshpande D; Magombedze G; Boorgula GD; Chapagain M; Srivastava S; Gumbo T
    J Infect Dis; 2024 Aug; 230(2):e230-e240. PubMed ID: 38036299
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Ceftriaxone 1 g versus 2 g per day, for the treatment of community-acquired pneumonia: a retrospective cohort study.
    Guz D; McNeil R; Buchrits S; Goshen S; Gafter-Gvili A; Avni T
    Intern Emerg Med; 2023 Oct; 18(7):1919-1927. PubMed ID: 37474675
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Variability in the serum and tissue concentrations of pre-incisional ceftriaxone for surgery in paediatric population and outcome of surgical-site infections; An open labelled, prospective, non-randomized, analytical study.
    Sheikh S; Majoka R; Tripathi CD; Verma V; Bagga D; Karim BA; Meshram GG
    Curr Res Pharmacol Drug Discov; 2022; 3():100082. PubMed ID: 35146418
    [TBL] [Abstract][Full Text] [Related]  

  • 108. TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.
    van Lieshout MH; van der Poll T; van't Veer C
    Inflamm Res; 2014 Nov; 63(11):927-33. PubMed ID: 25118783
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial.
    Mujagic E; Zwimpfer T; Marti WR; Zwahlen M; Hoffmann H; Kindler C; Fux C; Misteli H; Iselin L; Lugli AK; Nebiker CA; von Holzen U; Vinzens F; von Strauss M; Reck S; Kraljević M; Widmer AF; Oertli D; Rosenthal R; Weber WP
    Trials; 2014 May; 15():188. PubMed ID: 24885132
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Prevention of surgical site infection: beyond SCIP.
    Anderson DJ
    AORN J; 2014 Feb; 99(2):315-9. PubMed ID: 24472594
    [No Abstract]   [Full Text] [Related]  

  • 111. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.
    Lamb HM; Ormrod D; Scott LJ; Figgitt DP
    Drugs; 2002; 62(7):1041-89. PubMed ID: 11985490
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans.
    Martin C; Viviand X; Alaya M; Lokiec F; Ennabli K; Said R; Pecking M
    Antimicrob Agents Chemother; 1996 Mar; 40(3):812-5. PubMed ID: 8851621
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy.
    Martin C; Viviand X; Cottin A; Savelli V; Brousse C; Ragni E; Richaud C; Mallet MN
    Antimicrob Agents Chemother; 1996 May; 40(5):1311-3. PubMed ID: 8723493
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Pharmacokinetics and tissue penetration of a single dose of ornidazole (1,000 milligrams intravenously) for antibiotic prophylaxis in colorectal surgery.
    Martin C; Bruguerolle B; Mallet MN; Condomines M; Sastre B; Gouin F
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1921-4. PubMed ID: 2291657
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Ceftriaxone (1 g intravenously) penetration into abdominal tissues when administered as antibiotic prophylaxis during nephrectomy.
    Leone M; Albanèse J; Tod M; Savelli V; Ragni E; Rossi D; Martin C
    J Chemother; 2003 Apr; 15(2):139-42. PubMed ID: 12797390
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Pharmacokinetics and tissue penetration of single-dose cefotetan used for antimicrobial prophylaxis in patients undergoing colorectal surgery.
    Martin C; Portet C; Lambert D; Bruguerolle B; Sastre B; De Micco P; Gouin F
    Antimicrob Agents Chemother; 1992 May; 36(5):1115-8. PubMed ID: 1510402
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Penetration of ceftriaxone into the intervertebral disc.
    Lang R; Folman Y; Ravid M; Bental T; Gepstein R
    J Bone Joint Surg Am; 1994 May; 76(5):689-91. PubMed ID: 8175816
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery.
    Martin C; Ragni J; Lokiec F; Guillen JC; Auge A; Pecking M; Gouin F
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2804-7. PubMed ID: 1482149
    [TBL] [Abstract][Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.